Mercia Fund Management leads investment in telecoms start-up Birmingham, UK 20 August 2013. Smart Antenna Technologies (SAT) today announced the launch of its innovative single-antenna technology for mobile devices. The technology will enable smartphone and tablet device manufacturers to replace several antennae with a single multi-band antenna, the performance of which will match that of
Cambridge UK, 30 July 2013 – Antitope Ltd (“Antitope”), a PolyTherics company, today announced a research agreement with ChemomAb Ltd of Tel Aviv, Israel (“ChemomAb”) for the generation of therapeutic antibodies for development as potential new treatments for inflammatory diseases. Under this agreement, Antitope will apply its Composite Human AntibodyTM technology to generate fully humanised
PolyTherics and Antitope combine to offer technologies for the development of better biopharmaceuticals Warwick, UK, 26 July 2013 – Mercia Fund Management (MFM) announces that one of its portfolio companies, PolyTherics Limited (“PolyTherics”), has merged with Antitope Limited (“Antitope”), the leading provider of antibody engineering and immunogenicity screening services, to create an enlarged group with
Henley-in-Arden, 22 July 2013 – Venture capital fund manager Mercia Fund Management (MFM) has announced £150,000 of funding in Oxford Genetics Ltd. The new biotechnology company is behind SnapFast™ – a system that simplifies the purchase of synthetic DNA molecules (plasmids). CEO of Oxford Genetics, Dr Ryan Cawood, invented the SnapFast™ system and likens it
Founded in a hot bed of fresh thinking and unique ideas, university spin-outs are becoming increasingly popular with both savvy investors, who can achieve a healthy return, and universities benefiting from funding channelled back into their R&D and facilities. Working with eight Midlands’ universities, Mercia Fund Management (MFM) has supported spin-outs from seed to successful
ColoAd1 study to compare direct intra-tumoral with intravenous injection in patients with non-metastatic colorectal cancer OXFORD, UK – June 18, 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, will initiate a clinical trial of ColoAd1, a systemically available oncolytic vaccine, to compare the effectiveness of direct intra-tumoral injection with intravenous injection in
Henley-in-Arden, 13 June 2013 – Venture capital fund manager Mercia Fund Management (MFM) is pleased to announce that Ventive has been named national runner up in the Shell Springboard awards 2013. The awards were highly contested with 150 finalists from across the UK. In May, MFM announced that it participated in an equity raise of
Birmingham, UK, 21 May 2013, Irresistible Materials (IM), a UK materials technology company spun-out from the University of Birmingham, is pleased to announce £290,000 of further support from its investing shareholder Mercia Fund Management and new business angels from the US and UK, coupled with the appointment of Stuart McIntosh as its new Chairman. Stuart
Henley-in-Arden, 9 May 2013 – Venture capital fund manager Mercia Fund Management (MFM) has participated in an equity raise of more than £900,000 for Ventive Ltd. MFM joined an angel funding round which was also supported by the Angel Co-fund. Ventive, recently named as a regional winner in the prestigious Shell Springboard 2013 competition, develops
Experienced CMO to Oversee and Advance Clinical Oncology and Cachexia Programs OXFORD, UK – 8th May 2013 – PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, today announced that Dr. Christine Wilkinson Blanc has joined the company’s management team as Chief Medical Officer. In her new role, Dr. Wilkinson Blanc will focus her efforts